Misoprostol in the treatment of duodenal ulcer refractory to H2-blocker therapy. A placebo-controlled, multicenter, double-blind, randomized trial. 1987

R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb

A multicenter, double-blind, randomized study compared 200 micrograms of misoprostol and placebo four times daily for four weeks in the treatment of 225 patients with duodenal ulcer (0.7 cm to 2.0 cm in size) persisting after at least four weeks of adequate, conventional therapy with cimetidine or ranitidine. Misoprostol was significantly superior to placebo in healing duodenal ulcers (achieving a healing rate of 37 percent versus 22 percent in the placebo group [p = 0.02], and in relieving ulcer pain [p = 0.01]). Healing also occurred more frequently with misoprostol than with placebo in patients with subgroups of particularly resistant ulcers. In the treatment of ulcers refractory to at least eight weeks of histamine H2-blocker therapy, misoprostol achieved a healing rate of 42 percent versus 20 percent with placebo. In the treatment of pyloric channel ulcers, 28 percent of patients in the misoprostol group showed healing as compared with 20 percent in the placebo group. Diarrhea was reported by 15.4 percent and 3.4 percent of patients receiving misoprostol and placebo, respectively, and was usually mild and transient. Misoprostol is safe and effective therapy for duodenal ulcers that have not healed during the course of H2-blocker therapy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004381 Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM. Curling's Ulcer,Curling Ulcer,Curlings Ulcer,Duodenal Ulcers,Ulcer, Curling,Ulcer, Duodenal,Ulcers, Duodenal
D005260 Female Females
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
November 1985, Digestive diseases and sciences,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
February 1990, The Journal of rheumatology. Supplement,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
January 1981, Journal of clinical gastroenterology,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
December 1985, Singapore medical journal,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
February 1986, Digestive diseases and sciences,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
January 1982, Scandinavian journal of gastroenterology. Supplement,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
September 1985, Schweizerische medizinische Wochenschrift,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
April 2007, Arthritis and rheumatism,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
September 1991, Zeitschrift fur Gastroenterologie,
R D Newman, and N Gitlin, and E J Lacayo, and A V Safdi, and E J Ramsey, and S L Engel, and A Rubin, and C H Nissen, and E A Swabb
January 1984, Clinical and experimental pharmacology & physiology,
Copied contents to your clipboard!